{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T04:10:28Z","timestamp":1722226228200},"reference-count":15,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,7,28]]},"DOI":"10.7759\/cureus.65603","type":"journal-article","created":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T03:59:55Z","timestamp":1722225595000},"source":"Crossref","is-referenced-by-count":0,"title":["Safety Outcomes After Sacubitril\/Valsartan Initiation in a Community Teaching Hospital: A Retrospective Observational Study"],"prefix":"10.7759","author":[{"given":"Erin","family":"Anderson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Trager","family":"Hintze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nephy","family":"Samuel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000757","article-title":"Heart disease and stroke statistics\u20142020 update: a report from the American Heart Association","volume":"141","author":"Virani SS","year":"2020","unstructured":"Virani SS, Alonso A, Benjamin EJ, et al.. Heart disease and stroke statistics\u20142020 update: a report from the American Heart Association. Circulation. 2020, 141:e139-596. 10.1161\/CIR.0000000000000757","journal-title":"Circulation"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000001063","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on clinical practice guidelines","volume":"145","author":"Heidenreich PA","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, et al.. 2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on clinical practice guidelines. Circulation. 2022, 145:e895-1032. 10.1161\/CIR.0000000000001063","journal-title":"Circulation"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray JJV","year":"2014","unstructured":"McMurray JJV, Packer M, Desai AS, et al.. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014, 371:993-1004. 10.1056\/NEJMoa1409077","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-022-01545-1","article-title":"Effects of sacubitril\/valsartan on glycemia in patients with diabetes and heart failure: the PARAGON-HF and PARADIGM-HF trials","volume":"21","author":"Wijkman MO","year":"2022","unstructured":"Wijkman MO, Claggett B, Vaduganathan M, et al.. Effects of sacubitril\/valsartan on glycemia in patients with diabetes and heart failure: the PARAGON-HF and PARADIGM-HF trials. Cardiovasc Diabetol. 2022, 21:110. 10.1186\/s12933-022-01545-1","journal-title":"Cardiovasc Diabetol"},{"key":"ref5","unstructured":"Highlights of prescribing information. (2015). Accessed. Sep 15, 2023: https:\/\/www.novartis.com\/us-en\/sites\/novartis_us\/files\/entresto.pdf."},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812851","article-title":"Angiotensin-neprilysin inhibition in acute decompensated heart failure","volume":"380","author":"Velazquez EJ","year":"2019","unstructured":"Velazquez EJ, Morrow DA, DeVore AD, et al.. Angiotensin-neprilysin inhibition in acute decompensated heart failure. N Engl J Med. 2019, 380:539-48. 10.1056\/NEJMoa1812851","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.1498","article-title":"Initiation of sacubitril\/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised transition study","volume":"21","author":"Wachter R","year":"2019","unstructured":"Wachter R, Senni M, Belohlavek J, et al.. Initiation of sacubitril\/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised transition study. Eur J Heart Fail. 2019, 21:998-1007. 10.1002\/ejhf.1498","journal-title":"Eur J Heart Fail"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1080\/20009666.2019.1708638","article-title":"Evaluating the safety and tolerability of inpatient sacubitril\/valsartan initiation in a community hospital","volume":"10","author":"Peppin KL","year":"2020","unstructured":"Peppin KL, Tellor KB, Armbruster AL, Schwarze MW. Evaluating the safety and tolerability of inpatient sacubitril\/valsartan initiation in a community hospital. J Community Hosp Intern Med Perspect. 2020, 10:38-44. 10.1080\/20009666.2019.1708638","journal-title":"J Community Hosp Intern Med Perspect"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(17)30087-6","article-title":"Effect of sacubitril\/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial","volume":"5","author":"Seferovic JP","year":"2017","unstructured":"Seferovic JP, Claggett B, Seidelmann SB, et al.. Effect of sacubitril\/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial. Lancet Diabetes Endocrinol. 2017, 5:333-40. 10.1016\/S2213-8587(17)30087-6","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.121.008335","article-title":"Trends in 30- and 90-day readmission rates for heart failure","volume":"14","author":"Khan MS","year":"2021","unstructured":"Khan MS, Sreenivasan J, Lateef N, et al.. Trends in 30- and 90-day readmission rates for heart failure. Circ Heart Fail. 2021, 14:e008335. 10.1161\/CIRCHEARTFAILURE.121.008335","journal-title":"Circ Heart Fail"},{"key":"ref11","unstructured":"Overview of clinical conditions with frequent and costly hospital readmissions by payer, 2018. (2021). Accessed. Jul 23, 2022: https:\/\/hcup-us.ahrq.gov\/reports\/statbriefs\/sb278-Conditions-Frequent-Readmissions-By-Payer-2018.jsp."},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.2337\/diaclin.26.2.77","article-title":"Microvascular and macrovascular complications of diabetes","volume":"26","author":"Fowler MJ","year":"2008","unstructured":"Fowler MJ. Microvascular and macrovascular complications of diabetes. Clin Diabetes. 2008, 26:77-82. 10.2337\/diaclin.26.2.77","journal-title":"Clin Diabetes"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.27.10.2540","article-title":"Diabetic retinopathy","volume":"27","author":"Fong DS","year":"2004","unstructured":"Fong DS, Aiello LP, Ferris FL 3rd, Klein R. Diabetic retinopathy. Diabetes Care. 2004, 27:2540-53. 10.2337\/diacare.27.10.2540","journal-title":"Diabetes Care"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2003.00712.x","article-title":"Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64)","volume":"63","author":"Adler AI","year":"2003","unstructured":"Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR, UKPDS GROUP. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int. 2003, 63:225-32. 10.1046\/j.1523-1755.2003.00712.x","journal-title":"Kidney Int"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.26.6.1895","article-title":"The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta-analysis","volume":"26","author":"Maser RE","year":"2003","unstructured":"Maser RE, Mitchell BD, Vinik AI, Freeman R. The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta-analysis. Diabetes Care. 2003, 26:1895-901. 10.2337\/diacare.26.6.1895","journal-title":"Diabetes Care"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/252737-safety-outcomes-after-sacubitrilvalsartan-initiation-in-a-community-teaching-hospital-a-retrospective-observational-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T03:59:55Z","timestamp":1722225595000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/252737-safety-outcomes-after-sacubitrilvalsartan-initiation-in-a-community-teaching-hospital-a-retrospective-observational-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,28]]},"references-count":15,"URL":"https:\/\/doi.org\/10.7759\/cureus.65603","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7,28]]}}}